- Home
- OPHC vs LUNG Comparison
OPHC vs LUNG Comparison
Compare OPHC & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPHC | LUNG |
|---|---|---|
| Founded | 2000 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.8M | 72.2M |
| IPO Year | 2012 | 2020 |
Fundamental Metrics
Financial Performance| Metric | OPHC | LUNG |
|---|---|---|
| Price | $5.06 | $1.32 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 22.9K | ★ 715.9K |
| Earning Date | 05-11-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.64 |
| EPS | ★ 0.71 | N/A |
| Revenue | N/A | ★ $90,497,000.00 |
| Revenue This Year | $17,095.98 | $2.48 |
| Revenue Next Year | N/A | $18.46 |
| P/E Ratio | $7.08 | ★ N/A |
| Revenue Growth | N/A | ★ 8.01 |
| 52 Week Low | $3.76 | $1.13 |
| 52 Week High | $5.59 | $7.01 |
Technical Indicators
Market Signals| Indicator | OPHC | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 40.38 | 42.68 |
| Support Level | $4.00 | N/A |
| Resistance Level | $5.54 | $1.93 |
| Average True Range (ATR) | 0.13 | 0.11 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 18.97 | 32.87 |
Price Performance
Historical ComparisonAbout OPHC OptimumBank Holdings Inc.
OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides community banking services to individuals and corporate customers. Its services include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal accounts, money market deposit accounts, debit cards, and automated teller machines.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.